Top

Published in:

01-01-2013 | Research Paper

Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway

Authors: Lindsey Walker, Ana C. Millena, Nicole Strong, Shafiq A. Khan

Published in: Clinical & Experimental Metastasis | Issue 1/2013

Abstract

Transforming growth factor-β (TGFβ) is a secreted cytokine implicated as a factor in cancer cell migration and invasion. Previous studies have indicated that TGFβ isoforms may exert differential effects on cancer cells during different stages of the disease, however very little is known about the expression patterns and activity of the three isoforms in prostate cancer. Non-traditional signaling pathways including the PI3-Kinase have been associated with TGFβ-mediated effects on cancer cell invasion. In the present study, we have carried out expression analysis of TGFβ isoforms and signaling components in cell line models representing different stages of prostate cancer and studied the differential effects of specific isoforms on migratory and invasive behavior and induction of the PI3-kinase pathway. TGFβ1 and TGFβ3 were expressed in all cell lines, with TGFβ3 expression increasing in metastatic cell lines. Both TGFβ1 and TGFβ3 induced motility and invasive behavior in PC3 cells, however, TGFβ3 was significantly more potent than TGFβ1. TGFβRI and Smad3 inhibitors blocked TGFβ1 and TGFβ3 induced motility and invasion. TGFβ3 caused a significant increase in pAKT^ser473 in PC3 cells and PI3-kinase inhibitor LY294002 blocked TGFβ3 induced migration, invasion and phosphorylation of AKT. Both TGFβRI and Smad3 inhibitors blocked TGFβ3 induced pAKT^ser473. Based on these results, we conclude that TGFβ3 is expressed in metastatic prostate cancer cell lines and is involved in induction of invasive behavior in these cells. Furthermore, these effects of TGFβ3 are TGFβRI and Smad3 dependent and mediated via the PI3-kinase pathway.

Wakefield LM, Roberts AB (2002) TGF-beta signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 12(1):22–29PubMedCrossRef

Padua D, Massague J (2009) Roles of TGFbeta in metastasis. Cell Res 19(1):89–102PubMedCrossRef

Massague J, Blain SW, Lo RS (2000) TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103(2):295–309PubMedCrossRef

Verrecchia F, Mauviel A (2002) Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol 118(2):211–215PubMedCrossRef

Seoane J (2006) Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27(11):2148–2156PubMedCrossRef

Derynck R, Akhurst RJ, Balmain A (2001) TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29(2):117–129PubMedCrossRef

Bierie B, Moses HL (2009) Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 21(1):49–59PubMedCrossRef

Joshi A, Cao D TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci 15: 180-94

Baardsnes J et al (2009) TbetaR-II discriminates the high- and low-affinity TGF-beta isoforms via two hydrogen-bonded ion pairs. Biochemistry 48(10):2146–2155PubMedCrossRef

10.

Piek E, Heldin CH, Ten Dijke P (1999) Specificity, diversity, and regulation in TGF-beta superfamily signaling. Faseb J 13(15):2105–2124PubMed

11.

Rahimi RA, Leof EB (2007) TGF-beta signaling: a tale of two responses. J Cell Biochem 102(3):593–608PubMedCrossRef

12.

Laverty HG et al (2009) TGF-beta3 and cancer: a review. Cytokine Growth Factor Rev 20(4):305–317PubMedCrossRef

13.

Dickson MC et al (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121(6):1845–1854PubMed

14.

Sanford LP et al (1997) TGFbeta2 knockout mice have multiple developmental defects that are non-overlapping with other TGFbeta knockout phenotypes. Development 124(13):2659–2670PubMed

15.

Proetzel G et al (1995) Transforming growth factor-beta 3 is required for secondary palate fusion. Nat Genet 11(4):409–414PubMedCrossRef

16.

Kaartinen V et al (1995) Abnormal lung development and cleft palate in mice lacking TGF-beta 3 indicates defects of epithelial-mesenchymal interaction. Nat Genet 11(4):415–421PubMedCrossRef

17.

Wrana JL et al (1992) TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71(6):1003–1014PubMedCrossRef

18.

Cheifetz S et al (1990) Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. J Biol Chem 265(33):20533–20538PubMed

19.

De Crescenzo G et al (2003) Real-time monitoring of the interactions of two-stranded de novo designed coiled-coils: effect of chain length on the kinetic and thermodynamic constants of binding. Biochemistry 42(6):1754–1763PubMedCrossRef

20.

De Crescenzo G et al (2004) Enhancement of the antagonistic potency of transforming growth factor-beta receptor extracellular domains by coiled coil-induced homo- and heterodimerization. J Biol Chem 279(25):26013–26018PubMedCrossRef

21.

Lopez-Casillas F, Wrana JL, Massague J (1993) Betaglycan presents ligand to the TGF beta signaling receptor. Cell 73(7):1435–1444PubMedCrossRef

22.

Vilchis-Landeros MM et al (2001) Recombinant soluble betaglycan is a potent and isoform-selective transforming growth factor-beta neutralizing agent. Biochem J 355(Pt 1):215–222PubMedCrossRef

23.

Hart PJ et al (2002) Crystal structure of the human TbetaR2 ectodomain–TGF-beta3 complex. Nat Struct Biol 9(3):203–208PubMed

24.

Van Themsche C et al (2007) Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem 282(7):4794–4802PubMedCrossRef

25.

Karan D et al (2002) Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells. Carcinogenesis 23(6):967–975PubMedCrossRef

26.

Assinder SJ et al (2009) The TGF-beta, PI3 K/Akt and PTEN pathways: established and proposed biochemical integration in prostate cancer. Biochem J 417(2):411–421PubMedCrossRef

27.

Jiang BH, Liu LZ (2009) PI3 K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 102:19–65PubMedCrossRef

28.

Salmena L, Carracedo A, Pandolfi PP (2008) Tenets of PTEN tumor suppression. Cell 133(3):403–414PubMedCrossRef

29.

Bakin AV et al (2000) Phosphatidylinositol 3-kinase function is required for transforming growth factor beta-mediated epithelial to mesenchymal transition and cell migration. J Biol Chem 275(47):36803–36810PubMedCrossRef

30.

Lamouille S, Derynck R (2007) Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol 178(3):437–451PubMedCrossRef

31.

Shin I et al (2001) Transforming growth factor beta enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 12(11):3328–3329PubMed

32.

Vinals F, Pouyssegur J (2001) Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol Cell Biol 21(21):7218–7230PubMedCrossRef

33.

Wilkes MC et al (2005) Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 65(22):10431–10440PubMedCrossRef

34.

Zhong M et al (2010) Oxytocin induces the migration of prostate cancer cells: involvement of the Gi-coupled signaling pathway. Mol Cancer Res 8(8):1164–1172PubMedCrossRef

35.

Vo BT, Khan SA (2011) Expression of nodal and nodal receptors in prostate stem cells and prostate cancer cells: autocrine effects on cell proliferation and migration. Prostate 71(10):1084–1096PubMedCrossRef

36.

McDonald CA et al (2006) Follicle-stimulating hormone-induced aromatase in immature rat Sertoli cells requires an active phosphatidylinositol 3-kinase pathway and is inhibited via the mitogen-activated protein kinase signaling pathway. Mol Endocrinol 20(3):608–618PubMedCrossRef

37.

Massague J (1984) Type beta transforming growth factor from feline sarcoma virus-transformed rat cells. Isolation and biological properties. J Biol Chem 259(15):9756–9761PubMed

38.

Reinhold D et al (1997) Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells. Immunology 91(3):354–360PubMedCrossRef

39.

Jones E, Pu H, Kyprianou N (2009) Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 13(2):227–234PubMedCrossRef

40.

Amatschek S et al (2004) Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 64(3):844–856PubMedCrossRef

41.

Li C et al (1998) Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer. Int J Cancer 79(5):455–459PubMedCrossRef

42.

Blanco-Aparicio C et al (2007) PTEN, more than the AKT pathway. Carcinogenesis 28(7):1379–1386PubMedCrossRef

43.

Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657PubMedCrossRef

44.

Dubrovska A et al (2009) The role of PTEN/Akt/PI3 K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 106(1):268–273PubMedCrossRef

45.

Cao C et al (2006) Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 66(20):10040–10047PubMedCrossRef

46.

Festuccia C et al (2005) Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Endocr Relat Cancer 12(4):983–998PubMedCrossRef

47.

Huang H et al (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 276(42):38830–38836PubMedCrossRef

Title: Expression of TGFβ3 and its effects on migratory and invasive behavior of prostate cancer cells: involvement of PI3-kinase/AKT signaling pathway
Authors: Lindsey Walker
Ana C. Millena
Nicole Strong
Shafiq A. Khan
Publication date: 01-01-2013
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 1/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-012-9494-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Anti-LFA-1 antibodies enhance metastasis of ocular lymphoma to the brain and contralateral eye

Characterization of the inflammatory response to solid cancer metastases in the human brain

Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy

Development of a tridimensional microvascularized human skin substitute to study melanoma biology

NM23 deficiency promotes metastasis in a UV radiation-induced mouse model of human melanoma

Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood–brain barrier during extravasation and brain invasion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer